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Introduction: Post allogeneic HSCT chimerism analysis of
bone marrow (BM) and peripheral blood (PB) has been used
to monitor engraftment and to detect early disease recur-
rence. Mixed chimerism is occasionally encountered early
after RIC HSCT. The sensitivity of PB chimerism to detect
mixed BM chimerism remains to be determined. Our aim is
to determine the sensitivity of PB chimerism studies in pre-
dicting BMmixed chimerism post RIC allogeneic HSCT and to
determine the clinical relevance of early detection.
Methods: We did a retrospective review of chimerism data
from PB and BM samples from patients undergoing RIC
allogeneic HSCT from matched related, matched unrelated
and haploidentical donors. Chimerism data was collected
every 3 months during the ﬁrst year post HSCT. Only samples
drawn up to 5 days apart were included in the analysis.
Results: We analyzed 200 pairs of BM and PB samples in 89
patients with median age of 58 years (range 22-77). Of these,
132 pairs demonstrated </¼ 1% recipient cells in both
specimens (Marrow -, Blood -, M-B-), 45 pairs demonstrated
>1% recipient cells in both specimens (M+B+), 4 pairs had a
BM sample which showed </¼ 1% recipient cells and a PB
sample which showed >1% recipient cells (M-B+) and 19
pairs had a BM which showed >1% recipient cells and a PB
sample which showed </¼ 1% recipient cells (M+B-). The
ability of PB specimens to detect mixed BM chimerism
showed: 70% sensitivity, 97% speciﬁcity, positive predictive
value of 92%, and negative predictive value of 87%. The 19
M+B- specimens were from 16 patients (characteristics in
Table 1). Of these 16 patients, 4 relapsed (two at the time of
M+B-, one 22 days post-M+B-, and one 45months post-M+B-
) and 6 ultimately died (4 of relapse, 1 of infection, 1 of graftTable 1
Demographics
All patients Patients with M+/B- % M+/B-
Total patients 89 16 18%
Female 42 8 19%
Male 47 8 17%
Diagnosis
AML 26 4 15%
NHL 18 2 11%
MM 11 2 18%
CLL 7 4 57%
ALL 6 2 33%
Aplastic anemia 5 0 0%
Other 16 2 13%
Transplant type
Matched unrelated 16 2 13%
Matched related 28 4 14%
Haploidentical 45 10 22%
Status
Alive 49 10 20%
Deceased 40 6 15%vs. host disease). M+B- seen early post transplant (median
D+30) was not associated with relapse, while later detection
was associated with relapse (median D+137). The patients in
the M+/B- group who relapsed had acute leukemia (3/4) and
multiple myeloma (1/4).
Conclusions: PB chimerism had a high speciﬁcity; yet, it was
insufﬁciently sensitive (70%) to detect mixed BM chimerism
in patients undergoing RIC allogeneic HSCT. Though numbers
are small, peripheral blood samples best predict marrow
chimerism in patients with aplastic anemia rather than in
malignancies originating in the BM (leukemias and mye-
loma). Continued bone marrow sampling is thus required,
with the possible exception of patients transplanted for
aplastic anemia or malignancies not originating in the BM.360
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Low Dose Thymoglobulin Result in Improved Outcomes after
Allogeneic Unrelated Hematopoietic Stem Cell Trans-
plantation (HCT) for Patients with Acute Myeloid Leukemia/
Myelodysplastic Syndrome Conditioned with Intravenous
Busulfan and Fludarabine.
Intravenous Busulfan/Fludarabine (Bu/Flu) based condition-
ing regimens have resulted in lower treatment related mor-
tality (TRM) after allogeneic HCT in both reduced and full
intensity dosing in AML/MDS . The addition of thymoglobulin
to such regimens to minimize the risk of graft versus host
disease after unrelated donor (MUD) HCT has been linked to
the increased concerns of relapse risk.
Method: In order to study the impact of addition of low dose
thymoglobulin to Bu/Flu regimens in MUD recipients, the
medical records of 38 consecutive AML/MDS patients who
underwent MUD HCT with BU/Flu and low dose thymoglo-
bulin were retrospectively reviewed. All the patients
received single daily dose of iv Bu 3.2 mg/kg for 2 days (RIC,
Bu2-Flu) or 4 days (FIC, Bu4-Flu) based on age, older or
younger than 65 respectively. Fludarabine was given as a
single daily dose of 40 mg/Kg for 4 days. Graft versus host
Patient Characteristics n, (%)
Age, median (range), years 38(26-73)
Patients 55 years or older 23 Patients (60%)
Gender 18 Female, 20 Male
Diagnosis
AML/MDS 34/4
HLA
Match 10/10 36 patients (95%)
Match 9/10 2 Patients (5%)
Conditioning Regimen
Bu4Flu (FIC) 21 (55%)
Bu2Flu (RIC) 17 (45%)
Status at transplant
CR1 26 (68%)
CR2 3 (8%)
PIF 9 (24%)
CIBMTR risk
Low 28 (74%)
Intermediate 2(5%)
High 8(21%)
Cytogenetic risk
Low 24 (63%)
High 14 (37%)
CR¼complete remission, PIF¼ primary refractory
Table 1
Group Variables.
Variables Thiotepa (10) No Thiotepa (40) P-value
Median Range Median Range
Age (yr) 1.1 0.3- 15.5 0.9 0.1- 17.4 0.79
Infused TNC/kg8 1.21 0.37- 3.18 0.85 0.05- 4.27 0.52
Infused MNC/kg8 1.06 0.31- 2.83 0.73 0.04- 3.84 0.49
Infused CD34/kg6 0.83 0.10- 8.7 0.99 0.02- 7.6 0.31
N[ Percent N[ Percent
HLA Match 3/6, 4/6,
5/6, 6/6
0, 5,
5, 0
0, 50, 50, 0 3, 22,
8,7
8, 55, 20, 17 0.20
TBI 4 40 11 27.5 0.46
Table 2
Group Outcomes.
Outcomes Thiotepa (10) No Thiotepa
(40)
P-value
N¼ % N¼ %
Alive 9 90 21 52.5 0.037
TRM 0 0 13 32.5 0.045
Non-Engraft 1 10 13 32.5 0.07
Transplant Event 2 20 24 60 0.035
ANC Engraft 9 90 22 55 0.07
PLT Engraft 9 90 19 47.5 0.029
Chimerism >95% 9 90 17 42.5 0.006
EFS >5 yr 9 90 16 40 0.038
OS >5 yr 10 100 15 37.5 0.039
Ac GVHD 4 40 8 20 0.23
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cipients and Tacrolimus/Mycophenolate in RIC recipients.
Additionally, all the patients received thymoglobulin 1.5 mg/
Kg on day -3, -2 and -1. All patients received peripheral stem
cells except one patient with mismatch MD who received
bone marrow product.
Results: Patient Characteristics are shown in Table 1. All the
patient engrafted except one who received marrow product.
All the patients but 3 (8%) achieved 90% or more donor
chimerism by day 100. With Mean follow up of 500 days
(range, 100-1242) the overall survival (OS) was 77%  7 (CI
63-91%) at 1 year and 67%  9 (CI 49-85%) at 2 years. Simi-
larly, disease free survival was 66% 8 (CI 50-82%) at 1 and 2
years. Cumulative incidence of acute GVHD grade II-IV was
55% with grade III-IV 12%. Cumulative incidence of chronic
GVHD at 1 year was 43%with extensive chronic GVHD in 17%.
The regimen was associated with low treatment related
mortality (TRM) with cumulative incidence of only 5% at one
year, CI 14-21%. The cumulative incidence of relapse at one
year was 29%, CI 17-49%. On univariate analysis only high risk
CIBMTR status was predictive of poor OS (p¼0.05).
Conclusion: The addition of low dose thymoglobulin to RIC
and FIC regimens with iv Busulfan/Fludarabine prior to MUD
HCT results in low TRM and improved OS for patients with
AML/MDS. Relapse rate does not seem to be increased in this
cohort by the addition of low dose thymoglobulin in com-
parison to historical control.
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We retrospectively evaluated all CBT performed for non-
malignant conditions to determine if there is any correlation
between transplant outcomes & conditioning, including Total
body irradiation, Fludarabine, Cyclophosphamide, Etoposide
& Thiotepa.
Between 1/1995 & 1/2011, 50 CBT were performed. Condi-
tioning: TBI + VP16 + Cy (11); TBI + TT  VP16 + Cy (4); TT +
FLUD  Bu  VP16 (6); Bu + Cy (11); Bu + FLUD (15); VP + Cy
(2); no conditioning (1). Diagnoses: Immunodeﬁciency (22),
BM failure (10), Metabolic disease (6), Histiocytic disease (6),
Hemoglobinopathy (6).
There were 20 F, 30 M. Median age 1.0 yr (0.1 e17.4), wt 9.15
kg (3.0 - 52.0). HLA match: 6/6 (7), 5/6 (13), 4/6 (27), 3/6 (3).
Median cell dose/Kg: TNC 0.89
ˇ
8, MNC 0.77
ˇ
8, CD34 0.99
ˇ
6.
CBU were processed per Rubenstein et al. GvHD prophylaxis:
MTX + ATG + CSA (18); MMF + ATG + CSA (13); no MTX/MMF
(19); PRED or FK506 (10).
Statistical analysesweredoneusing Fisher’s Exact, Log-Rank,&
Column stats. Signiﬁcance was determined at p-value of 0.05.
Overall Results: 62% achieved ANC >500 cells/mL at 20 days
(11 - 40); 56% had PLT >20,000 at 40 d (14 - 100); & 52%
achieved>95% chimerism at 43 d (13 - 169). 13 pts died from
day + 100 TRM. 30pts are survivors at this time. EFS> 1, 3, 5 yr
was 44, 32 & 30%, with OS of 62, 46 & 42%. 8 pts are event free
>10 yr. Median follow up was 2.0 yr (0.2- 14.6 yr). Acute
GVHDgrade II - IVwas seen in 12, therewas no chronic GVHD.
Conclusion: In this cohort patients who received Thiotepa in
addition to other conditioning showed statistically signiﬁ-
cant transplant outcomes. There was no TRM. 5 yr OS was
100%, EFS 90%. Thiotepa recipients had better and rapid
